Boehringer Ingelheim and Baiji Shenzhou cooperate to promote new immunotumor drugs

"We are pleased to have such a significant partnership with bioxcellence, a leader in the biopharmaceutical industry We believe that the cooperation is an important milestone, which is conducive to promoting our candidate products into clinical practice " John v oyler, chief executive of Baiji, said, "we always adhere to our goal to develop innovative treatment solutions for cancer patients in China and around the world to meet their medical needs In the future, our product line will continue to maintain rapid development The high-quality production base and clinical production capacity of Boehringer Ingelheim is the key to help us achieve our goals and meet the quality and compliance requirements of China and the world " Mr Feng Baohe, a member of the Executive Board of Boehringer Ingelheim, said: "we are also very happy to cooperate with a growing biopharmaceutical company like Baiji Shenzhou Bringer Ingelheim is a global leader in biopharmaceutical R & D and production By bringing successful experience to China, we hope to help more Chinese Biopharmaceutical Enterprises like Baiji Shenzhou develop and produce biopharmaceuticals, so as to provide more high-quality products for Chinese patients " "Biopharmaceutics is one of our core businesses in China." Pan Dawei, President and CEO of Greater China of Boehringer ingelham, pointed out that "the cooperation with Baiji Shenzhou is of great significance to us With the support of relevant government departments in Shanghai and Pudong, we can jointly build and use the world-class Zhangjiang biopharmaceutical base " The picture shows the 3D effect picture of the Zhangjiang biopharmaceutical base of Boehringer Ingelheim Baiji Shenzhou (Beijing) Biotechnology Co., Ltd is a Chinese biotechnology and new drug creation company located in Zhongguancun Life Science Park, Beijing It is committed to the research and development of innovative anti-cancer drugs including new chemical small molecules and biological large molecules Through independent development of new drugs found in its Chinese laboratories and cooperation with pharmaceutical partners, Baiji has authorized the joint development of new drugs under development to meet the medical needs of cancer patients in China and Asia Baiji is creating a solid biomarker and bioinformatics platform to identify the subsets of cancer patients most likely to benefit from related drugs or treatment methods, and to develop more effective and safer targeted innovative drugs by studying the relationship between drug sensitivity and target molecules For more information, please visit About Boehringer Ingelheim group is one of the top 20 pharmaceutical companies in the world Headquartered in Ingelheim, Germany, the company has set up 142 subsidiaries around the world, with more than 47400 employees Since its founding in 1885, the family owned enterprise has been committed to the research and development, manufacturing and marketing of innovative drugs with high therapeutic value for humans and animals In 2013, the company's net sales were 14.1 billion euros, and its R & D investment was equivalent to 19.5% of the net sales of prescription drugs The contract manufacturing of Boehringer Ingelheim biopharmaceutical has now developed into a new brand - Boehringer Ingelheim bioxcellence As a leader in biomedical contract manufacturing with a history of more than 35 years, we have brought 22 biomedical products to the market About bringer Ingelheim China, which entered China in 1994, is headquartered in Shanghai At present, it has 3300 employees nationwide Its core businesses include prescription drugs, consumer independent health care, animal health care, biopharmaceutical, production, operation and R & D The company is committed to bringing more innovative drugs to the Chinese market In recent years, Boehringer Ingelheim China has maintained growth above the market average, and our vision is to become the leading multinational pharmaceutical company in China For more details, please visit